Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Cisplatin / Capecitabine	41
Overall Study	STARTED	Epirubicin / Cisplatin / Capecitabine	32
Overall Study	STARTED	Epirubicin / Oxaliplatin / Capecitabine	27
Overall Study	STARTED	Docetaxel / Cisplatin / Capecitabine	58
Overall Study	COMPLETED	Cisplatin / Capecitabine	10
Overall Study	COMPLETED	Epirubicin / Cisplatin / Capecitabine	9
Overall Study	COMPLETED	Epirubicin / Oxaliplatin / Capecitabine	7
Overall Study	COMPLETED	Docetaxel / Cisplatin / Capecitabine	26
Overall Study	NOT COMPLETED	Cisplatin / Capecitabine	31
Overall Study	NOT COMPLETED	Epirubicin / Cisplatin / Capecitabine	23
Overall Study	NOT COMPLETED	Epirubicin / Oxaliplatin / Capecitabine	20
Overall Study	NOT COMPLETED	Docetaxel / Cisplatin / Capecitabine	32

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00454636/flow